Mayo Clinic News Network

News Resources

Items tagged as "breast cancer"

Tuesday Q and A: Hormone replacement therapy may protect against health risks

DEAR MAYO CLINIC: I am 42 years old and have a BRCA1 gene mutation. I’ll have a prophylactic oophorectomy later this year. I have had a prophylactic mastectomy as well, and am considering hormone replacement therapy. How soon after surgery would I need to start taking hormones? What are the [...]

Created by lizatorborg

Mayo Clinic, University of North Florida Host Tenth Annual Upbeat Pink: A Musical Tribute to Breast Cancer Survivorship

JACKSONVILLE, Fla., Sept. 2, 2014 – Mayo Clinic and the University of North Florida are honoring National Breast Cancer Awareness Month in October by hosting the tenth annual “Upbeat Pink: A Musical Tribute to Breast Cancer Survivorship” concert on Friday, Oct. 10 at 7:30 p.m. in Lazzara Performance Hall, UNF [...]

Created by Paul Scotti

Monday's Housecall

THIS WEEK'S TOP STORIES Menopause hormone therapy: Pros and cons Hormone therapy can provide effective relief from menopause symptoms. Talk with your doctor to weigh your personal risks and benefits. Best sunscreen: Understand sunscreen options With so many types of sunscreen out there, it can be hard to know which [...]

Created by Dana Sparks

Breast Cancer Sisters: Mayo Clinic Radio Health Minute

In this Mayo Clinic Radio Health Minute, two sisters take very different approaches to breast cancer. To listen, click the link below. Breast Cancer Sisters

Created by Joel Streed

Estudo ALTTO sobre terapia combinada anti HER2, no Câncer de Mama, indica que um único agente, o Trastuzumabe, permanece como o padrão ouro de tratamento CHICAGO — No maior estudo clínico já realizado para analisar a eficácia do tratamento do câncer de mama HER2 positivo, com um ou com a combinação de dois medicamentos, os pesquisadores relataram que o uso do lapatinibe (Tykerb) não apresentou  benefício ao tratamento auxiliar padrão com trastuzumabe (Herceptin), conforme [...]

Created by Paul Scotti

Cáncer de mama: Estudio ALTTO sobre terapia combinada anti HER2, encuentra que agente único — el Trastuzumab — sigue siendo el mejor tratamiento estándar CHICAGO — En el mayor estudio clínico que prueba la eficacia de un tratamiento versus dos drogas para tratar el cáncer de mama HER2-positivo, lapatinib (Tykerb ) no agregó beneficio en relación a la terapia adyuvante estándar, trastuzumab (Herceptin), según informan investigadores de la 50a reunión anual de la [...]

Created by Paul Scotti

Mayo Clinic Study Finds Immunotherapy May be Option Challenging Breast Cancer

PHOENIX — A promising new study from Mayo Clinic, in conjunction with Caris Life Sciences, points to immunotherapy as a possible treatment option for patients with the difficult-to-treat triple negative breast cancer mutation. The study was presented this week at the 50th annual meeting of the American Society of Clinical Oncology [...]

Created by Admin

ALTTO Test of Dual HER2 Blockade Finds Single Agent - Trastuzumab - Remains Gold Standard Journalists: Broadcast soundbites with Dr. Perez are available in the downloads. CHICAGO — In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib (Tykerb) did not add benefit to the standard trastuzumab (Herceptin) adjuvant therapy, researchers report at the 50th [...]

Created by Paul Scotti

Load More